The Zhitong Finance App learned that on Thursday, Zaiding Pharmaceutical (ZLAB.US) surged more than 12% to $20.68. According to the news, Zaiding Pharmaceutical announced financial results for the second quarter of 2026. According to financial reports, total revenue for the second quarter of 2026 was US$106.3 million, and net product revenue was US$105.8 million, up 11% month-on-month, thanks to Zelle's steady performance and continued growth in sales of Agamod.

While the basic commercialization market is improving steadily, the company is also undergoing intensive regulatory progress in the oncology pipeline. Among them, the ADC drug Zocilurtatug Pelitecan (zoci) targeting DLL3 performed particularly well. In July 2026, Zaiding Pharmaceutical received zoci's orphan drug qualification (ODD) for the treatment of neuroendocrine cancers (NECs) from the US Food and Drug Administration (FDA). In June, Zaiding Pharmaceutical was granted the European Medicines Agency (EMA) certification by ZOCI as an orphan drug for the treatment of patients with pulmonary neuroendocrine cancer. In May, Zaiding Pharmaceutical was granted Fast Track Qualification (FTD) by the US FDA for the treatment of patients with extrapulmonary neuroendocrine cancer (EPNECs). This is the second FDA Fast Track qualification obtained by Zoci, and the company is actively communicating with regulators to advance the registration plan for the treatment of epnecs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.